The U.S. Food and Drug Administration has granted full, traditional approval to an Alzheimer's disease drug made by Eisai Inc. and Biogen Inc., six months after it won conditional approval from the same agency.
The U.S. Food and Drug Administration has granted full, traditional approval to an Alzheimer's disease drug made by Eisai Inc. and Biogen Inc., six months after it won conditional approval from the same agency.
